ASX RELEASE
2 May 2014

CEO Remuneration Package and Key Terms

Sydney, Australia and Bedminster, New Jersey – QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) has announced the remuneration details of Dr. Edward Rudnic, Chief Executive Officer, following today's announcement of his appointment.

The remuneration package and terms of employment has been set in alignment with QRxPharma's executive remuneration framework which provides a blend of fixed pay, short and long term performance incentives. The contract is effective from Dr. Rudnic's commencement date as Chief Executive Officer, 1 May 2014. The initial term is effective until 30 April 2016 and can be renewed in additional twelve-month periods.

Base Remuneration
Dr. Rudnic will receive an annual base salary of US$450,000.

Performance Incentive
A bonus of up to 50% of annual base salary will be paid upon the achievement of agreed performance targets. A quarter of the maximum annual bonus for the first year will be paid to Dr. Rudnic upon his commencement as Chief Executive Officer.

Additionally, in the event that the Company undergoes a change of control any time prior to the release of the results of any clinical trial that is a value changing event, the Company will pay a bonus equal to the annual base salary.

Share Options
Dr. Rudnic has been granted options over 4,500,000 shares in the Company with an exercise price of A$0.15 and an expiry date of 1 May 2021, in accordance with the terms of the Company's share option plan. These share options will vest over 3 years in tranches as follows:

One third on 1 May 2015 and thereafter the balance granted will vest in eight (8) equal tranches, one such tranche on the first day of each calendar quarter over the following two (2) years.

This share option grant represents 2.74% of the Company's issued capital.

Dr. Rudnic will be entitled to further participate in the Company's share and option plans.

Termination Payment
Payment of a termination benefit on early termination by the Company, other than for gross misconduct, equal to the annual base salary.

###

Media Contact Information:
Lisa Fels
Brightline Strategies
Tel: +1 703 739 2424 x110
Email: lfels@brightlinestrategies.com

Gavin Lower
Buchan Consulting
Tel: +61 414 796 726
Email: glower@buchanwe.com.au

About QRxPharma

QRxPharma Limited is an Australian based, commercial-stage specialty pharmaceutical company focused on the development and commercialisation of new pain management and abuse prevention products. The Company's product portfolio includes both late and early stage clinical drug candidates with the potential for reduced risks and improved patient outcomes. QRxPharma has entered into strategic agreements with Actavis Inc., Paladin Labs Inc., Aspen Group and Teva Pharmaceuticals for the commercialisation of immediate release Moxduo in the US, Canada, Australia (including New Zealand and Oceania), South Africa and Israel. The Company's clinical pipeline includes an intravenous (IV) and controlled release (CR) formulation of Moxduo. QRxPharma is also collaborating with Aesica Formulation Development Limited, for the worldwide promotion of QRxPharma's proprietary Stealth Beadlets™ abuse deterrence technology. For more information, visit www.qrxpharma.com.

Forward Looking Statements

This release contains forward-looking statements. Forward-looking statements are statements that are not historical facts; they include statements about our beliefs and expectations. Any statement in this release that states our intentions, beliefs, expectations or predictions (and the assumptions underlying them) is a forward-looking statement. These statements are based on plans, estimates and projections as they are currently available to the management of QRxPharma. Forward-looking statements therefore speak only as of the date they are made, and we undertake no obligation to update publicly any of them in light of new information or future events. By their very nature, forward-looking statements involve risks and uncertainties. A number of important factors could therefore cause actual results to differ materially from those contained in any forward-looking statement. Such factors include risks relating to the stage of products under development; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the commercialisation of the Company's proposed products.